心泰医疗（SCIENTECH）宣布，计划以人民币10.9亿元收购上海闵微生物科技54.2384%的股权。此举标志着心泰医疗在生物科技领域的战略布局进一步深化，旨在通过整合资源与技术，增强其在医疗器械及相关领域的核心竞争力。交易完成后，心泰医疗将成为上海闵微生物科技的控股股东，有望在研发、生产及市场拓展等方面实现协同效应。
心泰医疗（SCIENTECH）宣布，计划以人民币10.9亿元收购上海闵微生物科技54.2384%的股权。此举标志着心泰医疗在生物科技领域的战略布局进一步深化，旨在通过整合资源与技术，增强其在医疗器械及相关领域的核心竞争力。交易完成后，心泰医疗将成为上海闵微生物科技的控股股东，有望在研发、生产及市场拓展等方面实现协同效应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.